Nonalcoholic fatty liver disease

Journal of Lipid Research

Volumn 50, Issue SUPPL., 2009, Pages

  Erickson, Sandra K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Cirrhosis; Diabetes; Fibrosis; Liver tumors; Obesity; Steatohepatitis

Indexed keywords

ALCOHOL DERIVATIVE;

ANIMAL; DISEASE MODEL; FATTY LIVER; GENETICS; HUMAN; METABOLISM; REVIEW;

ALCOHOLS; ANIMALS; DISEASE MODELS, ANIMAL; FATTY LIVER; HUMANS;

EID: 66349125337     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R800089-JLR200     Document Type: Review

References (48)

1. Ludwig, J., T. R. Viggiano, D. B. Mc, and B. J. O. H. Gill. 1980. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55: 434-438. (Pubitemid 10057164)
2. Lazo, M., and J. M. Clark. 2008. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin. Liver Dis. 28: 339-350.
3. Ong, J. P., and Z. M. Younossi. 2007. Epidemiology and natural history of NAFLD and NASH. Clin. Liver Dis. 11: 1-16. (Pubitemid 46829973)
4. Marrero, J. A., R. J. Fontana, G. L. Su, H. S. Conjeevaram, D. M. Emick, and A. S. Lok. 2002. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 36: 1349-1354.
5. Bullock, R. E.,A. M. Zaitoun, G. P.Aithal, S. D.Ryder, I. J. Beckingham, and D. N. Lobo. 2004. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. J. Hepatol. 41: 685-686. (Pubitemid 39297808)
6. Chitturi, S., and G. C. Farrell. 2001. Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver Dis. 21: 27-41. (Pubitemid 32240484)
7. Utzschneider, K. M., and S. E. Kahn. 2006. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 91: 4753-4761. (Pubitemid 44917301)
8. Ramesh, S., and A. J. Sanyal. 2004. Hepatitis C and nonalcoholic fatty liver disease. Semin. Liver Dis. 24: 399-413. (Pubitemid 40052631)
9. Guaraldi, G., N. Squillace, C. Sentarelli, G. Orlando, R. D'Amico, G. Ligabue, F. Fiocchi, S. Zona, P. Loria, R. Esposito, et al. 2008. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin. Infect. Dis. 47: 250-257. (Pubitemid 351920629)
10. Merriman, R. B. 2006. Nonalcoholic fatty liver disease and HIV infection. Curr. HIV/AIDS Rep. 3: 113-117. (Pubitemid 44874996)
11. Targher, G., L. Bertolani, R. Padovani, S. Rodella, G. Zoppini, L. Zenari, M. Cigolini, G. Falezza, and G. Arcaro. 2006. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 29: 1325-1330. (Pubitemid 44125930)
12. Aygun, C., O. Kocaman, T. Sahin, S. Uraz, A. T. Eminler, A. Celebi, O. Senturk, and S. Hulager. 2008. Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. Dig. Dis. Sci. 53: 1352-1357. (Pubitemid 351514649)
13. Rubinstein, E., J. E. Levine, and J. B. Schwimmer. 2008. Hepatic, cardiovascular and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. Semin. Liver Dis. 28: 380-385.
14. Ong, J. P., A. Pitts, and Z. M. Younossi. 2008. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J. Hepatol. 49: 608-612.
15. Dunn, W., R. Xu, D. L. Wingard, C. Rogers, P. Angulo, Z. M. Younossi, and J. B. Schwimmer. 2008. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am. J. Gastroenterol. 103: 2263-2271.
16. Ratziu, V., F. Charlotte, A. Heurtier, S. Gombert, P. Giral, E. Bruckert, A. Grimaldi, F. Capron, and T. Poynard; LIDO Study Group. 2005. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 128: 1898-1906. (Pubitemid 40824701)
17. Yeh, M. M., and E. M. Brunt. 2007. Pathology of nonalcoholic fatty liver disease. Am. J. Clin. Pathol. 128: 837-847. (Pubitemid 350133997)
18. Merriman, R. B., L. D. Ferrell, M. G. Patti, S. R. Weston, M. S. Pabst, B. E. Aouizerat, and N. M. Bass. 2006. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology. 44: 874-880. (Pubitemid 46489551)
19. Angulo, P., J. M. Hui, G. Marchesini, E. Bugianesi, J. George, G. C. Farrell, F. Enders, S. Saksesa, A. D. Burt, J. P. Bida, et al. 2007. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 45: 846-854. (Pubitemid 46631552)
20. Munteanu, M., V. Ratziu, R. Morra, D. Messous, F. Imbert-Bismut, and T. Poynard. 2008. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: Fibro Test-Fibro-Max™ Experience. J. Gastrointestin. Liver Dis. 17: 187-191.
21. Wieckowska, A., and A. E. Feldstein. 2008. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin. Liver Dis. 28: 386-395.
22. Mofrad, P., M. J. Contos, M. Haque, C. Sargeant, R. A. Fisher, V. A. Lukethia, R. K. Sterling, M. L. Schiffman, R. T. Stravitz, and A. J. Sanyal. 2003. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 37: 1286-1292. (Pubitemid 36667307)
23. Schwimmer, J. B. 2007. Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents. Semin. Liver Dis. 27: 312-318. (Pubitemid 47301769)
24. Kershaw, E. E., and J. S. Flier. 2004. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89: 2548-2556. (Pubitemid 38766330)
25. Maher, J. J., P. Leon, and J. C. Ryan. 2008. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology. 48: 670-678.
26. Jou, J., S. S. Choi, and A. M. Diehl. 2008. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin. Liver Dis. 28: 370-379.
27. Willner, I. R., B. Waters, S. R. Patil, A. Reuben, J. Morelli, and C. A. Riely. 2001. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency and severity of disease. Am. J. Gastroenterol. 96: 2957-2961. (Pubitemid 32959539)
28. Struben, V. M., E. E. Hespenheide, and S. H. Caldwell. 2000. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am. J. Med. 108: 9-13. (Pubitemid 30058272)
29. Osterreicher, C. H., and D. A. Brenner. 2007. The genetics of nonalcoholic fatty liver disease. Ann. Hepatol. 6: 83-88. (Pubitemid 46879128)
30. Caldwell, S. H., D. M. Harris, J. T. Patrie, and E. E. Hespenheide. 2002. Is NASH underdiagnosed among African Americans? Am. J. Gastroenterol. 97: 1496-1500. (Pubitemid 34664799)
31. Browning, J. D., L. S. Szczepaniak, R. Dobbins, P. Nuremberg, J. D. Horton, J. C. Cohen, S. M. Grundy, and H. H. Hobbs. 2004. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 40: 1387-1395. (Pubitemid 39657013)
32. Browning, J. D., K. S. Kumar, M. H. Saboorian, and D. L. Thiele. 2004. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am. J. Gastroenterol. 99: 292-298. (Pubitemid 38279872)
33. Weston, S. R., W. Leyden, R. Murphy, N. M. Bass, B. P. Bell, M. M. Manos, and N. A. Terrault. 2005. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology. 41: 372-379. (Pubitemid 40165382)
34. Petersen, K. F., S. Dufour, J. Feng, D. Befroy, J. Dziura, C. D. Man, C. Cobelli, and G. I. Shulman. 2006. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc. Natl. Acad. Sci. USA. 103: 18273-18277. (Pubitemid 44871648)
35. Amarapurkar, D. N., E. Hashimoto, L. A. Lesmana, J. D. Sollano, P. J. Chen, and K. L. Goh. 2007. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J. Gastroenterol. Hepatol. 22: 788-793. (Pubitemid 46911047)
36. Fan, J. G., T. Saibara, S. Chitturi, B. I. Kim, J. J. Sung, and A. Chutaputti; Asia-Pacific Working Party for NAFLD. 2007. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J. Gastroenterol. Hepatol. 22: 794-800. (Pubitemid 46911036)
37. Romeo, S., J. Kozlitina, C. Xing, A. Pertsemlidis, D. Cox, L. A. Pennacchio, E. Boerwinkle, J. C. Cohen, and H. H. Hobbs. 2008. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40: 1461-1465.
38. Musso, G., R. Gambino, F. De Michieli, M. Durazzo, G. Pagano, and M. Cassader. 2008. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH. Hepatology. 47: 1167-1177. (Pubitemid 351547903)
39. Solga, S. F., and A. M. Diehl. 2003. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J. Hepatol. 38: 681-687. (Pubitemid 36560657)
40. Anstee, Q. M., and R. D. Goldin. 2006. Mouse models in nonalcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87: 1-16.
41. Rafiq, N., and Z. M. Younossi. 2008. Effects of weight loss on nonalcoholic fatty liver disease. Semin. Liver Dis. 28: 427-433.
42. Zivkovic, A. M., J. B. German, and A. J. Sanyal. 2007. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am. J. Clin. Nutr. 86: 285-300.
43. Verna, E. C., and P. D. Berk. 2008. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery. Semin. Liver Dis. 28: 407-426.
44. Browning, J. D. 2006. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology. 44: 466-471. (Pubitemid 44214886)
45. Ratziu, V., P. Giral, S. Jacqueminet, F. Charlotte, A. Hartemann-Heurtier, L. Serfaty, P. Podevin, J. M. Lacorte, C. Bernhardt, E. Bruckert, et al LIDO Study Group. 2008. Rosiglitazone for nonalcoholic steatohepatitis: one year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology. 135: 100-110. (Pubitemid 351916703)
46. Guruprasad, P. A., J. A. Thomas, P. V. Kaye, A. Lawson, S. D. Ryder, I.Spendlove, A. S. Austin, J. G. Freeman, L. Morgan, and J. Webber. 2008. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 135: 1176-1184.
47. Kashi, M. R., D. W. Torres, and S. A. Harrison. 2008. Current and emerging therapies in nonalcoholic fatty liver disease. Semin. Liver Dis. 28: 396-406.
48. Bellentani, S., R. Della Grave, A. Suppini, and G. Marchesini; Fatty Liver Italian Network. 2008. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology. 47: 746-754.